- Home
- QTRX vs CTNM Comparison
QTRX vs CTNM Comparison
Compare QTRX & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTRX
- CTNM
- Stock Information
- Founded
- QTRX 2007
- CTNM 2009
- Country
- QTRX United States
- CTNM United States
- Employees
- QTRX N/A
- CTNM N/A
- Industry
- QTRX Biotechnology: Laboratory Analytical Instruments
- CTNM
- Sector
- QTRX Industrials
- CTNM
- Exchange
- QTRX Nasdaq
- CTNM Nasdaq
- Market Cap
- QTRX 492.0M
- CTNM 453.0M
- IPO Year
- QTRX 2017
- CTNM 2024
- Fundamental
- Price
- QTRX $15.09
- CTNM $18.55
- Analyst Decision
- QTRX Strong Buy
- CTNM Strong Buy
- Analyst Count
- QTRX 4
- CTNM 4
- Target Price
- QTRX $23.00
- CTNM $29.25
- AVG Volume (30 Days)
- QTRX 372.5K
- CTNM 75.3K
- Earning Date
- QTRX 11-12-2024
- CTNM 11-06-2024
- Dividend Yield
- QTRX N/A
- CTNM N/A
- EPS Growth
- QTRX N/A
- CTNM N/A
- EPS
- QTRX N/A
- CTNM N/A
- Revenue
- QTRX $129,330,000.00
- CTNM N/A
- Revenue This Year
- QTRX $13.56
- CTNM N/A
- Revenue Next Year
- QTRX $16.61
- CTNM N/A
- P/E Ratio
- QTRX N/A
- CTNM N/A
- Revenue Growth
- QTRX 15.52
- CTNM N/A
- 52 Week Low
- QTRX $10.50
- CTNM $13.27
- 52 Week High
- QTRX $29.70
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- QTRX 69.72
- CTNM N/A
- Support Level
- QTRX $12.80
- CTNM N/A
- Resistance Level
- QTRX $13.73
- CTNM N/A
- Average True Range (ATR)
- QTRX 0.69
- CTNM 0.00
- MACD
- QTRX 0.31
- CTNM 0.00
- Stochastic Oscillator
- QTRX 88.89
- CTNM 0.00
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory, Homebrew - Custom Assay Development, and Uman NF-Light.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.